In conclusion, we developed a CSC model from a colorectal cancer patient-derived xenograft tumor and identified a PIK3CA (H1047R) mutation in the CSC population as a predictive biomarker to guide targeted therapy. The gene discussed is PIK3CA; the disease is neoplasm.